Capital Asset Advisory Services LLC Sells 98 Shares of Thermo Fisher Scientific Inc. $TMO

Capital Asset Advisory Services LLC trimmed its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% in the second quarter, Holdings Channel.com reports. The fund owned 6,514 shares of the medical research company’s stock after selling 98 shares during the quarter. Capital Asset Advisory Services LLC’s holdings in Thermo Fisher Scientific were worth $2,746,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Mondrian Investment Partners LTD increased its holdings in Thermo Fisher Scientific by 146.1% in the first quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company’s stock worth $106,738,000 after purchasing an additional 127,357 shares in the last quarter. GAMMA Investing LLC increased its holdings in Thermo Fisher Scientific by 22.0% in the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company’s stock worth $2,419,000 after purchasing an additional 877 shares in the last quarter. Advisors Capital Management LLC increased its holdings in Thermo Fisher Scientific by 6.7% in the first quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company’s stock worth $63,201,000 after purchasing an additional 7,967 shares in the last quarter. United Services Automobile Association bought a new stake in Thermo Fisher Scientific in the first quarter worth approximately $4,395,000. Finally, Ilmarinen Mutual Pension Insurance Co increased its holdings in Thermo Fisher Scientific by 5.3% in the first quarter. Ilmarinen Mutual Pension Insurance Co now owns 67,300 shares of the medical research company’s stock worth $33,488,000 after purchasing an additional 3,400 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the subject of a number of research analyst reports. Barclays upgraded Thermo Fisher Scientific from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $490.00 to $550.00 in a report on Thursday. Hsbc Global Res cut Thermo Fisher Scientific from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 24th. William Blair started coverage on Thermo Fisher Scientific in a research note on Monday, August 18th. They issued an “outperform” rating for the company. Scotiabank raised Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price objective for the company in a research note on Friday, July 11th. Finally, UBS Group raised their price objective on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a “neutral” rating in a research note on Thursday, July 24th. Seventeen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average target price of $592.24.

Thermo Fisher Scientific Stock Down 2.4%

Shares of NYSE:TMO opened at $479.48 on Friday. The stock has a market cap of $181.06 billion, a price-to-earnings ratio of 27.73, a PEG ratio of 2.62 and a beta of 0.75. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $623.77. The business’s 50 day moving average is $466.86 and its 200 day moving average is $451.08.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to analysts’ expectations of $10.68 billion. During the same quarter in the previous year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s payout ratio is currently 9.95%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of the business’s stock in a transaction on Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 30,066 shares of company stock valued at $14,182,963. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.